Pfizer and Alex Therapeutics announce a Strategic Commercial Partnership to provide evidence-based Digital Therapeutics to patients, starting in Germany
STOCKHOLM, Jan. 31, 2022 /PRNewswire/ -- The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world leading pharmaceutical company Pfizer have joined forces to provide evidence based, clinically validated and personalized digital therapies to patients. Together, the companies cover a broad range of expertise in the fields of medicine, marketing, clinical validation, AI, software development and psychology. The partnership...
Old Drugs Given New Life: Acura NanoMedicine Inc. Upgrades Existing Drugs Providing a More Efficient the Treatment for Cancer
TAIPEI, Dec. 14, 2021 /PRNewswire/ -- Taiwanese company Acura NanoMedicine Inc (https://www.acura-nanomed.com/), an award-winning health tech and biomedicine company, announces a groundbreaking nanotech-based solution to reduce instances of drug resistance and give new life to cancer treatments. Nine in Ten Refractory Tumor Face the Drug Resistance Related Issues Despite the progress made in current clinical...
Akeso Reported 2021 Annual Results
Penpulimab Started Commercialization and Cadonilimab Filed for NDA HONG KONG, April 1, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, reported 2021 annual results. Highlights: Anniko® (Penpulimab, AK105, PD-1) obtained market entry approval from the Chinese National Medical...
Medidata Veterans Rama Kondru and Sastry Chilukuri Named co-CEOs
SINGAPORE and SYDNEY, Oct. 1, 2021 /PRNewswire/ -- Medidata, a Dassault Systèmes company, recently named Rama Kondru and Sastry Chilukuri co-CEOs. Both are Medidata veterans, with Chilukuri as the founding president of Medidata Acorn AI and Kondru as executive vice president and chief technology officer. Collaborating as CEOs will be nothing new for...
Accelerate Innovation Towards the Future，SAB of Winhealth Pharma Formally Established
HANGZHOU, China, Oct. 12, 2021 /PRNewswire/ -- On October 12, 2021, Hong Kong Winhealth Pharma Group, (hereinafter referred to as "Winhealth Pharma") announced the formal establishment of its Scientific Advisory Board (SAB), aiming to further expand and optimize the Group's strategic layout in medical innovation, drug research & development, and other fields. With the help of SAB, Winhealth Pharma...
Enerjoy Launches Upgraded ShutEye 2.0 App to Provide Deeper Sleep Analysis
HONG KONG, Dec. 8, 2021 /PRNewswire/ -- Leading mobile sleep tracking application ShutEye has recently been upgraded to version 2.0. Developed by Enerjoy Limited, the application assists users in understanding their sleep quality and patterns by providing a comprehensive analysis of each night's rest. The upgrade will be available from December 20th, and will be complete with more functionality, a...
World’s First｜Aopeng Medical Completes Clinical Trial of Robotic-Assisted Peripheral artery Intervention of iliac artery in human
SHANGHAI, Nov. 24, 2021 /PRNewswire/ -- On November , 2021, Aopeng Medical's ALLVAS™ Endovascular Intervention Surgical Robot, successfully completed the first-in-human clinical evaluation of robot-assisted peripheral artery intervention of iliac artery in the Department of Vascular Surgery at Shanghai Changhai Hospital. The procedure was operated by Prof. Qing-Sheng Lu and his colleagues. The endovascular intervention surgical robot, combined with...
GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research
PERTH, Australia and TAIPEI and SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed in Perth, Australia in a phase Ib/II trial of GFH018 in combination with toripalimab (anti-PD-1 monoclonal antibody) as part of global multi-center...
James Dyson Award 2021: three winners with world-improving inventions
HOPES, A device for pain-free, at-home eye pressure testing, opening up access to glaucoma testing, by students of the National University of Singapore. Plastic Scanner, A low-cost, handheld device to identify plastic for recycling, by Jerry de Vos from TU Delft. REACT, A device to stem bleeding to help save the lives...
Ascletis’ Subcutaneous PD-L1 Antibody ASC22 Demonstrated Potential of Functional Cure of Chronic Hepatitis B as 42.9% of Patients with Baseline HBsAg≤100 IU/mL Obtained Sustained HBsAg Loss
--Ascletis presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for functional cure of CHB at oral session of EASL ILC 2022 on June 25, 2022, Beijing Time --The Phase IIb clinical trial results further demonstrated the potential of ASC22+NAs treatment as a functional cure for CHB --On-treatment ALT flares might be used as a predictor...
